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Objectives: We conducted a meta-analysis of randomized controlled trials (RCTs) and 
propensity score (PS) studies comparing survival and major adverse cardiac and 
cerebrovascular events (MACCEs) of patients who underwent coronary artery bypass 
grafting (CABG) with multiple (MAG) versus single arterial grafting (SAG). 
Methods: MEDLINE, Web of Science and Cochrane Library were used to find relevant 
literature (1960-2018). Survival at a follow-up ≥ 1 year, MACCEs and early outcomes 
were evaluated. Time-to-event outcomes were collected through hazard ratio (HR) along 
with their variance, and the other endpoints using frequencies from matched sample or 
adjusted odds ratios. Random effect models were used to compute combined statistical 
measures and 95% confidence intervals (CI) through generic inverse variance method 
(time-to-event) or Mantel-Haenszel method (binary events). 
Results: Twenty-nine PS cohorts and 8 RCTs comprising 122832 patients (52178 MAG 
and 70654 SAG) were included in this meta-analysis. MAG was associated with lower 
early mortality (OR: 0.82, 95%CI: 0.71-0.95, p=0.007), long-term mortality (HR: 0.76, 
95%CI: 0.73-0.78, p<0.001) and MACCEs (HR: 0.85, 95%CI: 0.79-0.91, p<0.001). 
Increased risk of sternal wound complications (SWC) was only observed when the 
bilateral internal mammary artery configuration was used for MAG (OR MAG BIMA: 
1.96, 95%CI: 1.37-2.81, p<0.001).  
Conclusion: Although the BIMA configuration increases the risk of SWC, MAG 





Although revascularization with an internal mammary artery graft to the left anterior 
descending artery is well established [1, 2], the survival benefit of adding other arterial 
conduits to the remaining vessels is still debated since it is based almost exclusively in 
observational studies [3]. The majority of non-experimental series evidenced a substantial 
survival benefit from both right internal mammary artery (RIMA) [4-6] and radial artery 
(RA) [7, 8] used as the second conduit compared with single internal mammary artery 
(SIMA) plus saphenous vein (SV) graft. However, the major randomized controlled trial 
(RCT) designed to answer the bilateral internal mammary artery (BIMA) vs. SIMA 
question, the Arterial Revascularization Trial (ART), failed to reach a positive result [9]. 
Not surprisingly, multiple arterial revascularization is not the mainstay at the majority of 
centres [10], despite most recent US [11] and European guidelines [12] as well as STS 
[13] recommendations.  
One of the main difficulties in implementation of the ART was the relatively high 
crossover rate from BIMA to SAG thus underlying the difficulty for the surgeons to 
implement the BIMA grafts in every case. To overcome some of the limitations in ART, 
the ROMA (Randomized comparison of the clinical Outcome of single versus Multiple 
Arterial grafts) trial [14], currently recruiting, was designed to compare any multiple 
arterial graft (MAG) configuration vs. SAG without imposing to the surgeon which graft 
configuration should be adopted. The ROMA trial results are expected to be reported in 
2030 and therefore there is a need to provide some interim guidance in the choice of 
arterial grafts. Previous meta-analyses have focused on single MAG configuration [15-
17]. Hence, we aim to conduct a meta-analysis which mimics the ROMA trial groups, 
including all MAG configurations in the MAG group (BIMA, SIMA+RA), compared 




To perform a meta-analysis of RCTs and PS studies, comparing MAG versus SAG topic 
in patients undergoing CABG. The main outcomes are long-term survival and major 
adverse cardiac and cerebrovascular events occurrence (MACCEs, death from any cause, 
stroke, myocardial infarction and/or repeat revascularization). Secondary endpoints 
include every individual event in the MACCEs composite outcome and early results, 
namely in-hospital death, sternal wound complications (SWC), repeat revascularization, 
stroke, myocardial infarction (MI) and re-intervention due to bleeding. 
Methods 
This study follows the PRISMA (Preferred Reporting Items for Systematic Review and 
Meta-analysis) statement (Table S1) [18]. MOOSE (Guidelines for Meta-Analyses and 
Systematic Reviews of Observational Studies) [19] items were also consulted and 
incorporated as adequate.  
Eligibility Criteria 
The search was limited by date of publication (January 1960–December 2018) and study 
language (English, Spanish or Portuguese) without geographical restrictions. 
We included RCTs that compared clinical outcomes after MAG vs. SAG and prospective 
or retrospective cohort studies using PS methodology which included at least 200 
patients. SAG was defined as any single arterial graft whereas MAG was defined as at 
least two arterial grafts. Supplemental grafts were allowed in both groups, except for 
additional arterial grafts in SAG. Studies with a follow-up period < 1 year, reviews, cross-
sectional studies, case-control studies, case series, case reports, abstracts conference 
presentations, editorials and expert opinions were excluded. Papers addressing outcomes 
in specific patient subgroups were also excluded. For the case of more than one article 
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reporting the same cohort, we included the one with either longer follow-up or larger 
sample size, whichever seemed more informative by author consensus. 
Information Sources 
Literature search was performed using MEDLINE, Web of Science and Cochrane Library 
databases. An additional manual search was done covering references of both original 
and review articles on the subject. 
Search Strategy 
After a free manual search, we defined both MeSH terms (controlled language) and free 
text terms to express each component of PICO expression: P) Population, coronary artery 
disease adult patients submitted to CABG procedure; I) Intervention, multiple arterial 
grafts; C) Comparison, single arterial graft and O) Outcomes, survival, MACCEs and in-
hospital endpoints. 
The detailed search queries are available at Tables S2 and S3. 
Study Records 
Data management 
Records identified in each database were imported and managed through EndNote Web 
and Microsoft Excel. Duplicates were automatically removed by software and manually 
confirmed.  
Selection process 
Two reviewers (FAS and JPLM) independently screened the titles and abstracts of all 
citations identified by the searches and compared the screening results for potentially 
eligible studies. All full texts of potentially eligible studies were retrieved and assessed 
for inclusion criteria by both reviewers. Discrepancies were settled by author consensus.  
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Data collection process 
Figure 1 depicts the flow process chart of study selection. Using a standardized form in 
Microsoft Excel, two reviewers (FAS and JPLM) extracted data into a database. 
Databases were compared and, in case of discrepancy, studies were double-checked by 
both reviewers for consistency. Authors of selected studies were not contacted to resolve 
missing or unclear reporting of data. 
Data items 
Both clinical and methodological data were gathered from the included studies using all 
data from text, tables and figures. Clinical definitions were considered as reported by each 
study and some categories were clustered for homogeneity. Study type, study period, 
country, overall and per group sample size, type of grafts, preoperative clinical 
characteristics including cardiovascular risk factors and comorbidities, operative data: 
off-pump CABG, number of grafts, follow-up duration and immediate and long-term 
outcomes were systematically collected.  
Both the primary endpoint and secondary endpoints were collected through treatment 
effect estimates derived from PS analysis or directly from intention-to-treat analysis of 
RCTs: hazard ratios (HR) and its variance for time-to-event analyses and odds ratio (OR) 
or absolute frequencies for immediate results. PS data items are described in 
Supplementary Appendix 3. One of these studies [20] provided two distinct cohorts 
contributing as two articles stated as Schwann 2014a and Schwann 2014b. Also, 
Benedetto and colleagues [21] provided a comprehensive comparison between MAG and 
SAG according to pump-status: off-pump subgroup stated as Benedetto 2017a and on-
pump stated as Benedetto 2017b. Regarding the study by Schwann et al. [22], which 
compared two distinct MAG groups (SIMA+RA and BIMA) with SAG, only the BIMA 
group was selected for comparison since the SIMA+RA group was too small to be also 
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compared with BIMA in matched triplets. Also, although our previous BIMA vs. SIMA 
study [23] did not meet this meta-analysis group definition as 10 patients within the SIMA 
group had one RA graft, we reanalysed the data excluding those patients. Finally, as 
patients randomized to SIMA group in the ART trial could receive radial arteries as 
supplementary grafts, we used data from the subgroup analysis without radial artery [9]. 
Risk of bias in individual studies 
The quality of observational included studies was assessed using the Newcastle-Ottawa 
Scale, maximum of nine stars [24] and RCTs using Cochrane scale [25]. 
Data analysis 
Continuous variables are expressed as mean ± standard deviation or median (interquartile 
range), as reported by authors. Categorical variables are reported as absolute and relative 
frequency (%) using the overall sample in both PS adjusted and PS stratification studies, 
using the matched cohort in PS matching (PSM) studies and the weighting cohort 
according to estimate sample size (ESS) in PS weighting (PSW) studies. SAG group was 
used as the reference category in all comparisons. The I2 was calculated for each analysis 
and heterogeneity was considered low (I2 <49%), moderate (I2 50-74%), or high (I2 > 
75%) [26].  
The primary outcomes, long-term survival and freedom from MACCEs, were assessed 
through adjusted or matched HR, and 95% confidence interval (CI) collected from the 
included studies. When not readily provided, HR was estimated from Kaplan Meier 
curves of PSM, PSW, or PS adjustment (PSA) groups using GetData Digitizer version 
2.26.0.20 application software and an R script provided by Guyot et al. [27]. When neither 
HR nor good-quality curves were available, we calculated the incidence rate ratio (IRR) 
if the number of events and mean follow-up was provided using metainc function of the 
meta R package [28] or relative risk (RR) if cumulative incidences were provided. 
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Pooled HR and 95% CI were computed by the generic inverse variance method using a 
random effect model.  
For the secondary endpoints, in PS matched cohorts we collected the number of events 
per group and calculated odds ratio whereas in PSW or PSA studies we collected the 
adjusted OR and computed pooled OR using the generic inverse variance method.  
Review Manager 5.3, as well as the meta [28] and metafor [29] packages based on the R 
environment (version 3.6.0) [30] were used to handle the extracted data.  
Risk of bias across studies 
The funnel plots, together with Egger’s linear regression method (metabias from the meta 
R package), were used to assess publication bias risk [31].   
Subgroup analysis 
Three subgroup analyses were performed: 1) according to study type: RCTs vs. PS; 2) 
according to follow-up time: short follow-up (mean/median follow-up <5 years), mid-
term follow-up (5 to 10 years) and long-term follow-up (≥10 years); and 3) according to 
MAG configuration (BIMA, SIMA+RA and BIMA or SIMA+RA). 
Results 
Selected studies 
Figure 1 presents the study flow diagram. From 642 titles, 180 were duplicates. The 
remaining 462 were screened by title and abstract and 133 were considered for full-text 
review. A total of 35 articles (37 cohorts) were considered for quantitative analysis.  
Study characteristics 
Table 1 presents the most relevant study characteristics and Table S4 details the pre-
operative and operative data.  
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The selected studies included 8 RCTs [9, 32-38] and 29 PS cohorts [6, 8, 20-23, 39-59]. 
The overall sample included 122832 patients (52178 MAG, 70654 SAG): 5095 from 
RCTs (2755 MAG, 2340 SAG) and 117737 from PS cohorts (49423 MAG, 68314 SAG).  
All the included studies reported survival results with mean follow-up time ranging from 
1 [32, 33, 35] to 16 years [49]. Eight studies (12344 MAG, 13858 SAG) reported follow-
up <5 years, 21 studies (31002 MAG, 47266 SAG) between 5 and 10 years, and 8 studies 
(8832 MAG, 9530 SAG) ≥10 years. In 16 studies MAG consisted of either BIMA or 
SIMA+RA (33741 MAG, 49099 SAG), in 12 of BIMA (11858 MAG, 14967 SAG) and 
the remaining 9 of SIMA+RA (6579 MAG, 6588 SAG).  
After applying PS methodologies, similar pre-operative characteristics were found 
between MAG and SAG in observational studies.  
Risk of bias within studies 
The Newcastle-Ottawa Scale and Cochrane Risk Bias confirmed good quality of the 
majority of included studies (Table S5).  
Primary Analysis  
Long-term survival 
Although several studies did not report the adjusted HR, it was derived from curves [6, 
20, 40, 41, 43, 49, 54, 57, 60] or by IRR [32, 33, 35-38] or RR estimation [58]. Overall, 
MAG significantly improved survival when compared to SAG (pooled HR: 0.76, 95%CI: 
0.73-0.78, p<0.001, Figure 2). A low grade of heterogeneity was found (I2 = 18%, 
p=0.18) mainly at the expense of observational studies (I2=12% vs. I2=0% for RCTs). No 
publication bias was detected (p=0.60, Figure S1A) 
As for the prespecified subgroup analyses, a significant difference was found regarding 
study type (p=0.005) showing high heterogeneity across subgroup results (I2 = 88%). 
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Although no significant differences were found across follow-up subgroups, studies with 
longer follow-up, over 10 years, presented the larger effect size, pooled HR: 0.74, 95%CI: 
0.67-0.81, while studies with follow-up between 5 and 10 years provided more precise 
estimates (pooled HR: 0.77, 95%CI:0.74-0.79, Figure S2) which can be partly ascribed 
to larger sample size. Also, MAG with BIMA configuration provided a larger, but less 
precise effect size (pooled HR: 0.74, 95%CI: 0.68-0.81, Figure S3). 
Long-term MACCEs 
Although 16 studies reported long-term MACCEs (different definitions of MACCEs 
adopted are given in Table S6), data in 2 RCTs [35, 36] was not suitable to be pooled and 
ART did not provide subgroup analysis for secondary endpoints. For Stand-in-Y trial 
[37], available data to pool just included SIMA+RA strategy, thus the aggregate estimate 
included 13 studies with 58019 patients (28530 MAG, 29489 SAG). We observed a 
significant 15% risk reduction in MAG (pooled HR: 0.85, 95%CI: 0.79-0.91, p<0.001, 
Figure 3) with moderate grade heterogeneity (I2=58%, p=0.005), mainly due to 
observational studies (I2= 67% vs. I2=1% in RCTs), and no publication bias (p=0.56, 
Figure S1B). 
No significant differences were found regarding the type of study (p=0.37) or length of 
follow-up (p=0.62, Figure S4) subgroup analyses. Still, a higher effect size was found 
for the longer follow-up subgroup (>10-years pooled HR: 0.80, 95%CI: 0.70-0.90). 
Stratifying according to MAG configuration was based on 2 studies for BIMA and 
another 2 for SIMA+RA configurations while the remaining 9 studies allowed both 
configurations. No subgroup differences were found (p=0.44; Figure S5) 
Secondary Endpoints 
Long-term stroke, myocardial infarction and re-revascularization are presented in 




Thirty-two studies reported early mortality as defined in Table S6. Four were excluded 
from analysis: 1 RCT reported zero events [38], ART did not provide this data for the 
subgroup analysis [9] and 2 PS studies [6, 52] did not report adjusted values. Although 
only 1 out of 28 included studies showed significant benefit in early mortality [21], the 
pooled estimate showed 18% risk reduction for MAG (OR: 0.82, 95%CI: 0.71-0.95, 
p=0.007, Figure S8). We found neither significant heterogeneity (I2=0%) nor publication 
bias (p=0.58, Figure S11A).  
Sternal Wound Complications 
From 26 studies that quantified SWC according to Table S6 definitions, 8 were excluded: 
2 for encompassing the in-hospital period [32, 44], 1 because no events were reported 
[46], 4 PS studies due to lack of adjusted data [6, 48, 52, 55] and ART which did not 
report this outcome for the no RA analysis [9]. MAG showed 50% increased risk for SWC 
(OR: 1.50, 95%CI: 1.12-2.01, p=0.006, Figure S9), but this was entirely attributable to 
the BIMA configuration as confirmed in the prespecified subgroup analysis (p=0.002 for 
subgroup differences, OR BIMA: 1.96, 95%CI: 1.37-2.81). A low grade of heterogeneity 
was found (I2=45%) more marked within the BIMA subgroup (I2=25% vs. I2=0% within 
the other two subgroups). No publication bias was detected (p=0.15, Figure S11B).   
Other early results, including re-revascularization, stroke, MI and re-intervention due to 
bleeding, are presented in Supplementary Appendix 2.  
Discussion 
Though observational studies have consistently supported the use of MAG compared with 
SAG showing better survival for multivessel coronary artery disease, and despite the 
noticeable difference in angiographic patency between arterial and vein grafts on follow-
up [61], surprisingly the largest RCT addressing this issue to date, ART, had neutral 
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outcomes. Raising substantial debate between practitioners that favour one approach over 
the other, various issues in RCT implementation have been proposed as reasonable 
explanations for the neutral results. Indeed, the as treated analysis of ART also supports 
lower 10-year mortality and MACCEs with MAG. The ROMA trial was designed as a 
multicentre international event-driven RCT powered to detect differences in MACCEs 
and finally address the issue of MAG vs. SAG as CABG standard of care [14]. To the 
best of our knowledge, this is the first meta-analysis of PS observational and RCT studies 
performed to date comparing patients submitted to CABG with MAG vs. SAG, regardless 
of the technique used. We pooled data from 122832 patients enrolled in PS -matched, -
adjusted, -weighted or –stratified observational cohort studies and previous RCTs.  
Interpretation of individual studies is limited by lack of randomization, small sample size 
for estimating survival outcome (all but one RCT <1000 patients), short length of follow-
up (14% PS cohorts and 50% RCTs <5 years) and representativeness of general real-
world practice. Although we limited observational study inclusion solely to studies that 
employed PS, mitigating some of the drawbacks of observational studies by offering a 
quasi-randomized selection of patients [62], we must still acknowledge that unmeasured 
confounders are not a straightforward topic [63].  
Nevertheless, the weight of observational studies remained the main contributor to the 
outcomes of this meta-analysis (weight in long-term survival outcome: 95.8% for PS and 
4.2% for RCTs). Even if treatment effect in both RCTs and PS studies shows the same 
trend towards a benefit from MAG, a significant difference across the type of study 
subgroup was uncovered, supporting the need for ROMA trial to address this issue. As 
previously reported by Dahabreh and colleagues [64], it would be expected that PS studies 
will show an extreme magnitude of the treatment effect when compared to RCTs. This 
could be attributed to a differential publication bias. While small or neutral effects from 
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observational studies are unlikely to be accepted for publication or even submitted, 
similar results from RCTs have a higher likelihood of being submitted and accepted for 
publication [65]. The highly selective samples for RCTs could also contribute for 
subgroup differences.  
Previous RCTs addressing MAG vs. SAG are underpowered for long-term survival 
estimation, having angiographic primary outcomes and short follow-up. The Stand-in-Y 
trial [37] randomized 815 patients to one of 4 strategies, 3 of them constituting MAG, and 
although no survival advantage was reported in any study group, a significant benefit in 
MACCEs for the 3 MAG groups comparing with SAG (appropriate data to pool not 
available) was reported. These results emphasize the limited power for this study to report 
survival differences for the short 2-years of follow-up, the wide-ranging confidence 
interval, and its reduced weight for the pooled survival result (0.2%). Indeed, sample size 
estimation was done using historical data for the expected rate of graft failure outcome. 
CARRPO [32] and Goldman et al. [33] trials’ sample size were also estimated accounting 
for 5- and 1-year graft patency outcomes, respectively, and both presented results for 1-
year survival (3 and 16 deaths, each) totalizing a 0% and  0.1% of weighting for this meta-
analysis. Differential crossover rates were reported in several trials: CARRPO [32], 
Goldman [33], Myers [36] and ART [9] trials crossover from arterial to conventional 
group were 7%, 9%, 4% and 14% of patients, respectively, representing higher rates than 
the reverse crossover from conventional to arterial group (2%, 1%, 1% and 4%). Besides 
that, within CARRPO and Myers trials the arterial group included 8 out of 161 and 8 out 
of 81 patients, respectively, with only one arterial conduit. Even if SAVE RITA 
(SAphenous Vein versus Right Internal Thoracic Artery as a Y-Composite Graft trial) 
[34] and Petrovic and colleagues [38] reported 5- and 8-years clinical outcomes, the 
former was designed to 1-year angiographic patency and the latter had randomized only 
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200 patients, without a prespecified assumption. ART is the only included RCT that was 
specifically designed for 10-year death from any-cause and its results contributed to 3.5% 
of the pooled result.  
Besides the lack of level 1 evidence, MAG is not the mainstay in CABG due to higher 
complexity of surgical technique, concerns about SWC and early “quality metrics”, 
increasing number of elderly high-risk patients, lack of surgical experience or simply 
inertial hurdles [66, 67]. These hurdles became noticeably clear in ART considering its 
differential crossover rates and the modification of effect according to surgeon volume. 
Indeed, surgical centre experience partly dictates long-term outcomes from BIMA 
grafting [67].  
Our results corroborate the concerns regarding SWC: there was a nearly 2-fold increase 
in the risk of SWC in MAG with BIMA grafting configuration, which was not the case 
with other configurations. Nevertheless, MAG was associated with reduced mortality on 
long-term follow-up (24% and 26% risk reduction overall and in studies over 10-years of 
follow-up, respectively), as well as with reduced MACCEs incidence (20% risk reduction 
on follow-up over 10 years) and even with lower rates of early mortality (18% risk 
reduction) thereby clearly offsetting the drawback of SWC in the BIMA subset of MAG 
patients. Conforming to these results, recent meta-analyses have shown a survival benefit 
of BIMA over SIMA grafting [15, 68, 69] and SIMA+RA over SIMA [17]. 
Concerning graft configurations in MAG, Benedetto and colleagues published a meta-
analysis of PS matched studies that reported superiority of BIMA configuration over 
SIMA+RA in long-term survival, freedom from repeat revascularization and similar early 
mortality and SWC when skeletonized harvesting was used [70]. Cumulative evidence 
regarding skeletonized harvesting supports lack of increased risks of SWC [71, 72], and 
this is the recommended harvesting technique by ESC guidelines mainly in groups at high 
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risk of SWC, such as diabetic patients [73]. We found reports on type of ITA harvesting 
in 5 out of 7 studies considered in our SWC results of BIMA vs. SAG [22, 36, 39, 51, 
59]. The heterogeneity amongst studies precludes considerations on the role of 
skeletonized harvesting.  
 
Study limitations 
The present meta-analysis has limitations: i) diversity of study design, patient’s selection 
and PS models; ii) heterogeneity regarding endpoint definitions; iii) although adjusted 
outcomes were analysed, selection bias in observational studies might have contributed 
to better results since usually younger and healthier patients are selected for MAG and 
“eye-balling” from surgeon experience [63], cannot be measured; iv) RCTs were scarce 
and had shorter follow-up periods; and, finally, v) the role of comorbidities and specific 
patient subgroups were not assessed and which subgroup of patients is more likely to 
benefit from MAG is still to be determined. 
Conclusion 
Pooling data of RCTs and PS studies comparing MAG vs. SAG CABG, showed a benefit 
of MAG in long-term survival and MACCEs, as well as early survival, although the 




Legends of Figures 
FIGURE 1. Flow chart for study selection. PS, propensity score. 
FIGURE 2. Forest plot comparing the effect of multiple arterial (MAG) versus single 
arterial grafting (SAG) on late mortality after coronary artery bypass grafting across 
individual studies and through pooled estimates. IV, inverse variance; PS, propensity 
score; RCT, randomized controlled trial; SE, standard error. 
FIGURE 3. Forest plot comparing the effect of multiple arterial (MAG) versus single 
arterial grafting (SAG) on long-term incidence of major adverse cardiac and 
cerebrovascular events (MACCEs) after coronary artery bypass grafting across individual 
studies and through pooled estimates. IV, inverse variance; PS, propensity score; RCT, 




1. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-
artery graft on 10-year survival and other cardiac events. The New England journal of 
medicine. 1986;314(1):1-6. 
2. Boylan MJ, Lytle BW, Loop FD, et al. Surgical treatment of isolated left anterior 
descending coronary stenosis. Comparison of left internal mammary artery and venous 
autograft at 18 to 20 years of follow-up. J Thorac Cardiovasc Surg. 1994;107(3):657-62. 
3. Gaudino M, Bakaeen FG, Benedetto U, et al. Arterial Grafts for Coronary Bypass: 
A Critical Review After the Publication of ART and RADIAL. Circulation. 
2019;140(15):1273-84. 
4. Dorman MJ, Kurlansky PA, Traad EA, Galbut DL, Zucker M, Ebra G. Bilateral 
internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-
up of propensity score-matched cohorts. Circulation. 2012;126(25):2935-42. 
5. Galbut DL, Kurlansky PA, Traad EA, Dorman MJ, Zucker M, Ebra G. Bilateral 
internal thoracic artery grafting improves long-term survival in patients with reduced 
ejection fraction: a propensity-matched study with 30-year follow-up. J Thorac 
Cardiovasc Surg. 2012;143(4):844-53.e4. 
6. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-
year follow-up defines survival benefit for second internal mammary artery in propensity-
matched groups. Ann Thorac Surg. 2010;90(1):101-8. 
7. Schwann TA, Al-Shaar L, Tranbaugh RF, et al. Multi Versus Single Arterial 
Coronary Bypass Graft Surgery Across the Ejection Fraction Spectrum. Ann Thorac 
Surg. 2015;100(3):810-7. 
8. Benedetto U, Codispoti M. Age cutoff for the loss of survival benefit from use of 
radial artery in coronary artery bypass grafting. J Thorac Cardiovasc Surg. 
2013;146(5):1078-84. 
9. Taggart DP, Benedetto U, Gerry S, et al. Bilateral versus Single Internal-Thoracic-
Artery Grafts at 10 Years. New England Journal of Medicine. 2019;380(5):437-46. 
10. Head SJ, Borgermann J, Osnabrugge RL, et al. Coronary artery bypass grafting: 
Part 2-optimizing outcomes and future prospects. European heart journal. 
2013;34(37):2873-86. 
11. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for 
Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol. 2011;58(24):e123-e210. 
12. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on 
myocardial revascularization. European heart journal. 2018;40(2):87-165. 
13. Aldea GS, Bakaeen FG, Pal J, et al. The Society of Thoracic Surgeons Clinical 
Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. The 
Annals of Thoracic Surgery. 2016;101(2):801-9. 
14. Gaudino M, Alexander JH, Bakaeen FG, et al. Randomized comparison of the 
clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and 
study protocol. Eur J Cardiothorac Surg. 2017;52(6):1031-40. 
15. Buttar SN, Yan TD, Taggart DP, Tian DH. Long-term and short-term outcomes 
of using bilateral internal mammary artery grafting versus left internal mammary artery 
grafting: a meta-analysis. Heart. 2017;103(18):1419-26. 
16. Gaudino M, Rahouma M, Abouarab A, et al. Radial artery versus saphenous vein 
as the second conduit for coronary artery bypass surgery: A meta-analysis. J Thorac 
Cardiovasc Surg. 2019;157(5):1819-25.e10. 
17. Gaudino M, Lorusso R, Rahouma M, et al. Radial Artery Versus Right Internal 
Thoracic Artery Versus Saphenous Vein as the Second Conduit for Coronary Artery 
18 
 
Bypass Surgery: A Network Meta-Analysis of Clinical Outcomes. J Am Heart Assoc. 
2019;8(2):e010839. 
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. Journal of clinical 
epidemiology. 2009;62(10):1006-12. 
19. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in 
epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) group. Jama. 2000;283(15):2008-12. 
20. Schwann TA, Tranbaugh RF, Dimitrova KR, et al. Time-varying survival benefit 
of radial artery versus vein grafting: a multiinstitutional analysis. Ann Thorac Surg. 
2014;97(4):1328-34  
21. Benedetto U, Caputo M, Mariscalco G, et al. Impact of multiple arterial grafts in 
off-pump and on-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg. 
2017;153(2):300-9.e6. 
22. Schwann TA, Hashim SW, Badour S, et al. Equipoise between radial artery and 
right internal thoracic artery as the second arterial conduit in left internal thoracic artery-
based coronary artery bypass graft surgery: a multi-institutional studydagger. Eur J 
Cardiothorac Surg. 2016;49(1):188-95. 
23. Saraiva FA, Girerd N, Cerqueira RJ, et al. Survival after bilateral internal 
mammary artery in coronary artery bypass grafting: Are women at risk? Int J Cardiol. 
2018;270:89-95. 
24. Wells GA SB, O’Connell D, Peterson J, Welch V, Tugwell P. The Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 
. 3rd Symposium on Systematic Reviews: Beyond the Basics. 2000;July 3–5. 
25. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Cochrane Handbook for 
Systematic Reviews of Interventions version 6.0 (updated July 2019) Chapter 8: 
Assessing risk of bias in a randomized trial. Cochrane, editor2019 Available from 
https://training.cochrane.org/handbook/current/chapter-08#section-8-9. 
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in 
meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557-60. 
27. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of 
survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC 
Medical Research Methodology. 2012;12(1):9. 
28. Schwarzer G. Meta: An R package for meta-analysis. R News. 2007;7(3):40-5. 
29. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. 
Journal of Statistical Software. 2010;36(3). 
30. R Core Team. R: A language and environment for statistical computing. . R 
Foundation for Statistical Computing. (2019). 
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected 
by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629-34. 
32. Damgaard S, Wetterslev J, Lund JT, et al. One-year results of total arterial 
revascularization vs. conventional coronary surgery: CARRPO trial. European heart 
journal. 2009;30(8):1005-11. 
33. Goldman S, Sethi GK, Holman W, et al. Radial artery grafts vs saphenous vein 
grafts in coronary artery bypass surgery: a randomized trial. Jama. 2011;305(2):167-74. 
34. Kim MS, Hwang HY, Kim JS, Oh SJ, Jang MJ, Kim KB. Saphenous vein versus 
right internal thoracic artery as a Y-composite graft: Five-year angiographic and clinical 
results of a randomized trial. J Thorac Cardiovasc Surg. 2018;156(4):1424-33.e1. 
19 
 
35. Muneretto C, Negri A, Manfredi J, et al. Safety and usefulness of composite grafts 
for total arterial myocardial revascularization: a prospective randomized evaluation. J 
Thorac Cardiovasc Surg. 2003;125(4):826-35. 
36. Myers WO, Berg R, Ray JF, et al. All-artery multigraft coronary artery bypass 
grafting with only internal thoracic arteries possible and safe: a randomized trial. Surgery. 
2000;128(4):650-9. 
37. Nasso G, Coppola R, Bonifazi R, Piancone F, Bozzetti G, Speziale G. Arterial 
revascularization in primary coronary artery bypass grafting: Direct comparison of 4 
strategies--results of the Stand-in-Y Mammary Study. J Thorac Cardiovasc Surg. 
2009;137(5):1093-100. 
38. Petrovic I, Nezic D, Peric M, et al. Radial artery vs saphenous vein graft used as 
the second conduit for surgical myocardial revascularization: long-term clinical follow-
up. J Cardiothorac Surg. 2015;10:127. 
39. Benedetto U, Amrani M, Gaer J, et al. The influence of bilateral internal mammary 
arteries on short- and long-term outcomes: a propensity score matching in accordance 
with current recommendations. J Thorac Cardiovasc Surg. 2014;148(6):2699-705. 
40. Bisleri G, Di Bacco L, Turturiello D, et al. Improved Outcomes of Total Arterial 
Myocardial Revascularization in Elderly Patients at Long-Term Follow-Up: A 
Propensity-Matched Analysis. Ann Thorac Surg. 2017;103(2):517-25. 
41. Buxton BF, Shi WY, Tatoulis J, Fuller JA, Rosalion A, Hayward PA. Total arterial 
revascularization with internal thoracic and radial artery grafts in triple-vessel coronary 
artery disease is associated with improved survival. J Thorac Cardiovasc Surg. 
2014;148(4):1238-43. 
42. DeSimone JP, Malenka DJ, Weldner PW, et al. Coronary Revascularization With 
Single Versus Bilateral Mammary Arteries: Is It Time to Change? Ann Thorac Surg. 
2018;106(2):466-72. 
43. Garatti A, Castelvecchio S, Canziani A, et al. Long-term results of sequential vein 
coronary artery bypass grafting compared with totally arterial myocardial 
revascularization: a propensity score-matched follow-up studydagger. Eur J Cardiothorac 
Surg. 2014;46(6):1006-13. 
44. Goldstone AB, Chiu P, Baiocchi M, et al. Second Arterial Versus Venous 
Conduits for Multivessel Coronary Artery Bypass Surgery in California. Circulation. 
2018;137(16):1698-707. 
45. Guru V, Fremes SE, Tu JV. How many arterial grafts are enough? A population-
based study of midterm outcomes. J Thorac Cardiovasc Surg. 2006;131(5):1021-8. 
46. Lin J, Cheng W, Czer LS, et al. Coronary artery bypass graft surgery using the 
radial artery as a secondary conduit improves patient survival. J Am Heart Assoc. 
2013;2(4):e000266. 
47. Locker C, Schaff HV, Dearani JA, et al. Multiple arterial grafts improve late 
survival of patients undergoing coronary artery bypass graft surgery: analysis of 8622 
patients with multivessel disease. Circulation. 2012;126(9):1023-30. 
48. Luthra S, Leiva-Juarez MM, John A, Matuszewski M, Morgan IS, Billing JS. A 
second arterial conduit to the circumflex circulation significantly improves survival after 
coronary artery bypass surgery. Eur J Cardiothorac Surg. 2018;53(2):455-62. 
49. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM. 
The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative 
years. Ann Thorac Surg. 2004;78(6):2005-12;. 
50. Pu A, Ding L, Shin J, et al. Long-term Outcomes of Multiple Arterial Coronary 
Artery Bypass Grafting: A Population-Based Study of Patients in British Columbia, 


























TABLE 1 – Overview of propensity score studies and randomized controlled trials included in the quantitative synthesis 






Study Period Follow-up 
Benedetto 2013  UK PSM SIMA + RA 9005 8069 809 936 809 March 1996 to May 2012 5 to 10 years 
Benedetto 2014  UK PSM BIMA 4195 3445 750 750 750 April 2001 - May 2013 < 5 years 
Benedetto 2017a UK PSW BIMA or SIMA + RA 6230 4412 ESS: 2567 1818 ESS: 739 1996- April 2015 5 to 10 years 
Benedetto 2017b  UK PSW BIMA or SIMA + RA 6402 5194 ESS: 3972 1208 ESS: 388 1996- April 2015 5 to 10 years 
Bisleri 2017  Italy PSM BIMA or SIMA + RA (TA) 973 587 151 386 151 March 1999 - May 2004 5 to 10 years 
Buxton 2014  Australia  PSM BIMA or SIMA + RA (TA) 3774 786 384 2988 384 January 1995 - 2010 > 10 years 
DeSimone 2018  UK PSM/PSA/PSW BIMA 47984 46502 1297 1482 1297 1992 - 2014 > 10 years 
Garatti 2014  Italy PSM BIMA or SIMA + RA (TA) 2306 2097 243 209 209 January 1994 - December 1996 > 10 years 
Goldstone 2018  USA PSM BIMA or SIMA + RA 59432 53566 5813 5866 5813 January 2006 - July 2011 5 to 10 years 
Grau 2012 USA PSM BIMA 6313 4854 928 1459 928 January 1994 - December 2010 5 to 10 years 
Guru  2006  Canada PSM BIMA or SIMA + RA  53727 47214 5491 6513 5491 September 1991 - March 2002 5 to 10 years 
Kurlansky 2010  USA PSM/PSS BIMA 4584 2369 2197 2215 2197 February 1972 - May 1994 > 10 years 
Lin 2013  USA PSM SIMA + RA 1248 NR 260 NR 260 January 1997 - December 2001 5 to 10 years 
Locker 2012  USA PSM BIMA or SIMA + RA  8622 7435 1153 1187 1153 January 1993 - December 2009 5 to 10 years 
Luthra 2018  UK PSM BIMA or SIMA + RA 3995 2757 1226 1238 1226 October 2004 - March 2014 5 to 10 years 




PSM BIMA or SIMA + RA 1419 963 432 456 432 March 2005 - April 2008 5 to 10 years 
Pu 2017  Canada PSW/PSM BIMA or SIMA + RA 20076 14496 4842 5580 4842 January 2000 - December 2014 5 to 10 years 
Puskas  2012  Georgia PSA BIMA 3527 2715 NA 812 NA January 2002 - December 2010 < 5 years 
Raja 2010  England PSA BIMA or SIMA + RA (TA) 1386 806 NA 580 NA September 1998 - September 2008 5 to 10 years 
Rocha 2018  Canada PSM BIMA or SIMA + RA  50230 38951 8629 11279 8629 October 2008 - March 2016 < 5 years 
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BIMA, bilateral internal mammary artery; ESS – estimated sample size; MAG – multiple arterial graft; NA – not applicable; NR – not reported; PSA – propensity score adjustment; PSM – propensity score matching; 
PSS – propensity score stratification; PSW – propensity score weighting; RA – radial artery; RCT – randomized controlled trial; SAG – single arterial graft; SIMA – single internal mammary artery; TA – total arterial.  
 
 
Saraiva 2018  Portugal PSW BIMA 2414 1478 ESS: 1992 936 ESS: 1460 January 2004-December 2013 5 to 10 years 
Schwann 2014a  USA PSM SIMA + RA 4908 2547 1799 2361 1799 1996-2006 5 to 10 years 
Schwann 2014b USA PSM SIMA + RA 4944 2974 995 1970 995 1995-2011 5 to 10 years 
Schwann 2016  USA PSM/PSM+PSA BIMA 5125 4484 551 641 551 1987-2011 > 10 years 
Shi 2016  Australia  PSM SIMA + RA  4006 786 507 3220 507 1995-2010 5 to 10 years 
Stevens 2004  Canada PSS BIMA 4382 2498 NA 1808 NA March 1985 – April 1995 > 10 years 
Tranbaugh 2015 USA PSM/PSA SIMA + RA 4945 2975 1023 1970 1023 January 1995 - June 2011 5 to 10 years 
Zacharias 2004 USA PSM SIMA + RA 3161 1869 925 1292 925 January 1996 - December 2002 < 5 years 
Damgaard 2009 Denmark RCT SIMA + RA 331 170 NA 161 NA February 2002-February 2005 < 5 years 
Goldman 2011  USA RCT SIMA + RA 733 367 NA 366 NA February 2003 - February 2008 < 5 years 
Kim 2018  South Korea RCT BIMA 224 112 NA 112 NA September 2008 - October 2011 5 to 10 years 
Muneretto 2003  Italy RCT BIMA or SIMA + RA (TA) 200 100 NA 100 NA 1999-2001 < 5 years 
Myers 2000  USA RCT BIMA (TA) 162 81 NA 81 NA January 1990 - December 1994 5 to 10 years 
Nasso 2009  Italy RCT BIMA or SIMA + RA 803 202 NA 601 NA January 2003 - April 2006 < 5 years 




RCT BIMA 2442 1208 NA 1234 NA June 2004 - December 2007 > 10 years 
